RxDoctor Payments DataLook up a doctor →

David Greenstein, MD

Dermatology · Beverly, MANPI 1205931789

Payments from drug & device makers

$4,035,195in general payments, 2019–2025

Across 2,412 payments — averaging $1672.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$1M
  • Eli Lilly$723K
  • Amgen$441K
  • Janssen Research & Development, LLC$288K
  • AbbVie$223K
  • Incyte Corporation$201K
  • plus $1.1M from 45 others
$49,530in research payments, 2019–2025

Across 21 payments — averaging $2358.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$36K
  • Eli Lilly$11K
  • Almirall LLC$3K

What the payments were for

  • Consulting fees$30,0406%
  • Speaking & faculty fees$439,88981%
  • Grants$880%
  • Travel & lodging$33,7906%
  • Food & beverage$35,5807%
  • Education$7740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,035,195 in reported general payments places this provider in the 95th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$1,188,298
Medicare patients
2,486
Services billed
15,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa21$412,494
Taltz AutoinjectorIxekizumab52$404,171
Dupixent PenDupilumab93$349,040
Humira(Cf) PenAdalimumab41$274,206
StelaraUstekinumab11$213,016
Enbrel SureclickEtanercept13$94,162
Dupixent SyringeDupilumab25$92,783
OtezlaApremilast19$68,968
OpzeluraRuxolitinib Phosphate12$29,737
VtamaTapinarof17$22,294
Acitretin23$21,850
BotoxOnabotulinumtoxina11$12,944
Clobetasol Propionate109$6,713
Fluorouracil109$6,577
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc75$4,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$2,875$213,01611 claims
AmgenOtezla$440,742$68,96819 claims
Incyte CorporationOpzelura$200,979$29,73712 claims
Dermavant Sciences, Inc.Vtama$63,072$22,29417 claims
AbbVieBotox$222,729$12,94411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in Beverly

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →